Abstract:Malignant hematopoietic cells gain metabolic plasticity, reorganize anabolic mechanisms to improve anabolic output and prevent oxidative damage, and bypass cell cycle checkpoints, eventually outcompeting normal hematopoietic cells. Current therapeutic strategies of acute myeloid leukemia (AML) are based on prognostic stratification that includes mutation profile as the closest surrogate to disease biology. Clinical efficacy of targeted therapies, e.g., agents targeting mutant FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1 or 2, are mostly limited to the presence of relevant mutations. Recent studies have not only demonstrated that specific mutations in AML create metabolic vulnerabilities but also highlighted the efficacy of targeting metabolic vulnerabilities in combination with inhibitors of these mutations. Therefore, delineating the functional relationships between genetic stratification, metabolic dependencies, and response to specific inhibitors of these vulnerabilities is crucial for identifying more effective therapeutic regimens, understanding resistance mechanisms, and identifying early response markers, ultimately improving the likelihood of cure. In addition, metabolic changes occurring in the tumor microenvironment have also been reported as therapeutic targets. The metabolic profiles of leukemia stem cells (LSCs) differ, and relapsed/refractory LSCs switch to alternative metabolic pathways, fueling oxidative phosphorylation (OXPHOS), rendering them therapeutically resistant. In this review, we discuss the role of cancer metabolic pathways that contribute to the metabolic plasticity of AML and confer resistance to standard therapy; we also highlight the latest promising developments in the field in translating these important findings to the clinic and discuss the tumor microenvironment that supports metabolic plasticity and interplay with AML cells.

Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells

The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting

Leukemic stem cells and therapy resistance in acute myeloid leukemia

Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development

Leukemia Stem Cells: the Root of Chronic Myeloid Leukemia

Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?

Molecular Characteristics of Leukemia Stem Cells and Up-Dating Therapeutic Strategy

Metabolic dependencies of acute myeloid leukemia stem cells

Mechanisms of Resistance to Targeted Therapies in AML

Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells

Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications

Re-Evaluation of Various Molecular Targets Located on Cd34(+)Cd38(-)Lin(-) Leukemia Stem Cells and Other Cell Subsets in Pediatric Acute Myeloid Leukemia

Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia

The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies

Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia

Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia

An arms‐race against resistance: leukemic stem cells and lineage plasticity

Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities

Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective

Resistance to targeted therapies in acute myeloid leukemia

Epigenetic mechanisms controlling human leukemia stem cells and therapy resistance